FDA's plan for cell and tissue-based products

WASHINGTON - The FDA announced on Friday a plan for "reinventing" the regulation of products derived from cells and tissues.

The proposed regulatory framework addresses a wide variety of therapies, including somatic cell therapy, the use of blood from the placenta and umbilical cord, and processed structural

Read the full 462 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers